Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BNGO 
Bionano Genomics Inc (BNGO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BNGO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $9.5
1 Year Target Price $9.5
| 0 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -56.45% | Avg. Invested days 10 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 18.02M USD | Price to earnings Ratio - | 1Y Target Price 9.5 |
Price to earnings Ratio - | 1Y Target Price 9.5 | ||
Volume (30-day avg) 4 | Beta 2.06 | 52 Weeks Range 2.68 - 30.52 | Updated Date 08/28/2025 |
52 Weeks Range 2.68 - 30.52 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -43.87 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.54 | Actual -1.99 |
Profitability
Profit Margin -271.02% | Operating Margin (TTM) -115.85% |
Management Effectiveness
Return on Assets (TTM) -30.86% | Return on Equity (TTM) -118.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21396900 | Price to Sales(TTM) 0.66 |
Enterprise Value 21396900 | Price to Sales(TTM) 0.66 | ||
Enterprise Value to Revenue 0.78 | Enterprise Value to EBITDA -0.18 | Shares Outstanding 4681000 | Shares Floating 4678004 |
Shares Outstanding 4681000 | Shares Floating 4678004 | ||
Percent Insiders 0.04 | Percent Institutions 2.26 |
Upturn AI SWOT
Bionano Genomics Inc
Company Overview
History and Background
Bionano Genomics Inc. was founded in 2003. The company develops and markets optical genome mapping solutions. Initially focused on nanotechnology for drug discovery, it pivoted to genome analysis. Key milestones include the development of the Saphyr system and its increasing adoption in cytogenetics and cancer research.
Core Business Areas
- Optical Genome Mapping (OGM): Bionano's core business revolves around its Saphyr system, which uses optical genome mapping to detect structural variations in DNA. This technology is used in research and diagnostics.
- Consumables: The company sells consumables for the Saphyr system, including chips and reagents.
- Services: Bionano provides OGM services to customers who prefer to outsource their genome mapping needs.
Leadership and Structure
Erik Holmlin, PhD, is the President and CEO. The company operates with a typical corporate structure with departments for research, development, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- Saphyr System: The Saphyr system is Bionano's flagship product, used for optical genome mapping. It competes with traditional cytogenetic methods like karyotyping and FISH, as well as next-generation sequencing (NGS) for structural variant detection. No definitive market share data is publicly available. Competitors: Illumina, Pacific Biosciences, Oxford Nanopore Technologies, Thermo Fisher Scientific.
- Saphyr Chips and Reagents: Consumables required for running the Saphyr system. Revenue is directly tied to Saphyr system usage. No definitive market share data is publicly available. Competitors: Illumina, Pacific Biosciences, Oxford Nanopore Technologies, Thermo Fisher Scientific.
Market Dynamics
Industry Overview
The genomics market is rapidly growing, driven by advancements in sequencing and mapping technologies. There's increasing demand for tools that can accurately detect structural variations, which are often missed by traditional methods.
Positioning
Bionano positions itself as a leader in optical genome mapping, offering a unique solution for comprehensive structural variation analysis. Its competitive advantage lies in its ability to detect large structural variants with high accuracy and cost-effectiveness compared to NGS.
Total Addressable Market (TAM)
The TAM for structural variation analysis is estimated to be in the billions of dollars, encompassing research, diagnostics, and drug development. Bionano is positioned to capture a significant portion of this market with its OGM technology.
Upturn SWOT Analysis
Strengths
- Unique optical genome mapping technology
- High accuracy in detecting structural variations
- Potential for cost-effectiveness compared to NGS
- Growing adoption in cytogenetics and cancer research
Weaknesses
- Limited market share compared to NGS leaders
- High reliance on Saphyr system sales
- Requires specialized expertise to operate
- Cash burn rate
Opportunities
- Expanding applications in diagnostics and drug discovery
- Partnerships with research institutions and pharmaceutical companies
- Developing new OGM-based assays
- Increasing awareness and adoption of OGM technology
Threats
- Competition from established NGS providers
- Technological advancements in NGS that improve structural variation detection
- Regulatory hurdles for diagnostic applications
- Economic downturn affecting research budgets
Competitors and Market Share
Key Competitors
- ILMN
- PACB
- TMO
- ONT.L
Competitive Landscape
Bionano faces strong competition from established NGS providers like Illumina and Thermo Fisher Scientific. Its advantage lies in its unique OGM technology, but it needs to continue to innovate and expand its market presence to compete effectively.
Major Acquisitions
OpGen's Acuitas AMR Gene Panel Business
- Year: 2020
- Acquisition Price (USD millions): 7.6
- Strategic Rationale: To expand Bionano's presence in the infectious disease market.
Growth Trajectory and Initiatives
Historical Growth: Bionano has experienced rapid revenue growth in some years, driven by increased adoption of the Saphyr system. However, growth has been inconsistent.
Future Projections: Analysts project continued revenue growth for Bionano, driven by expanding applications of OGM and increasing market penetration. However, profitability remains a challenge.
Recent Initiatives: Recent initiatives include expanding the Saphyr system's capabilities, developing new assays, and forging partnerships with research institutions and pharmaceutical companies.
Summary
Bionano Genomics is a company with innovative optical genome mapping technology that addresses the structural variation analysis market. While the technology shows promise and growth potential, Bionano is still an early-stage company with low market penetration in comparison with Illumina and has a history of net losses. The company should watch out for the competitors who provide the alternative NGS technology. If they were able to overcome these challenges then they should continue growing into the diagnostic and drug discovery markets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Press Releases, Analyst Reports, Industry News
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bionano Genomics Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2018-08-21 | President, CEO, CFO & Director Dr. Robert Erik Holmlin M.B.A., Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 98 | Website https://bionano.com |
Full time employees 98 | Website https://bionano.com | ||
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr and Stratys instruments, which are single-molecule imagers; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA; and Ionic purification system, which isolates and purifies nucleic acid molecules. In addition, the company offers Saphyr, Stratys, and Bionano compute servers; and VIA software, which offers one solution for analysis and interpretation of genomic data from microarray and sequencing data for cytogenetics and molecular genetics. Further, it provides testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.